Study reviews risk of recurrence in infants treated with anti-VEGF for ROP

Recurrence is not uncommon in infants with certain types of retinopathy of prematurity who were treated with intravitreal bevacizumab monotherapy, according to a study. Incidence of recurrence in the infants was 8.3%.The retrospective case series looked at rate and patterns of recurrence in 471 eyes of 241 infants with type 1 ROP, divided into stage 3+ ROP and aggressive posterior ROP, in zone I or zone II posterior who were treated with intravitreal Avastin (bevacizumab, Genentech) as monotherapy. Dose was 0.625 mg, given in accordance with the BEAT-ROP study protocol.